TRIB3 and hepatocellular carcinoma: Notably, also in such a model, knockout of TRIB3 accentuated sorafenib's therapeutic effect, fostering sustained hepatoma regression, although this treatment marginally affected hepatoma growth in the absence of sorafenib (Figure 1H–J; Figure S1E,F, Supporting Information).